🇺🇸 FDA
Pipeline program

PG2

DMR100-IRB-185

Phase 2 small_molecule completed

Quick answer

PG2 for Acute Stroke is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Acute Stroke
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials